Selvita Past Earnings Performance
Past criteria checks 5/6
Selvita has been growing earnings at an average annual rate of 38.3%, while the Life Sciences industry saw earnings growing at 15.4% annually. Revenues have been growing at an average rate of 32.9% per year. Selvita's return on equity is 20%, and it has net margins of 19.4%.
Key information
38.3%
Earnings growth rate
20.3%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 32.9% |
| Return on equity | 20.0% |
| Net Margin | 19.4% |
| Next Earnings Update | 25 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Selvita makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 337 | 65 | 198 | 0 |
| 31 Dec 23 | 352 | 70 | 206 | 0 |
| 30 Sep 23 | 358 | 20 | 205 | 0 |
| 30 Jun 23 | 369 | 31 | 209 | 0 |
| 31 Mar 23 | 372 | 24 | 215 | 0 |
| 31 Dec 22 | 365 | 26 | 212 | 0 |
| 30 Sep 22 | 364 | 20 | 219 | 0 |
| 30 Jun 22 | 351 | 11 | 220 | 0 |
| 31 Mar 22 | 329 | 12 | 211 | 0 |
| 31 Dec 21 | 316 | 15 | 198 | 0 |
| 30 Sep 21 | 260 | 12 | 162 | 0 |
| 30 Jun 21 | 216 | 18 | 131 | 0 |
| 31 Mar 21 | 181 | 22 | 105 | 0 |
| 31 Dec 20 | 142 | 18 | 85 | 0 |
| 30 Sep 20 | 158 | 21 | 92 | 0 |
| 30 Jun 20 | 99 | 15 | 58 | 0 |
| 31 Mar 20 | 63 | 9 | 36 | 0 |
| 31 Dec 19 | 54 | 7 | 30 | 0 |
| 30 Sep 19 | 22 | 2 | 14 | 0 |
| 31 Mar 19 | 81 | 10 | 49 | 0 |
| 31 Dec 18 | 77 | 10 | 47 | 0 |
| 31 Dec 17 | 56 | 4 | 36 | 0 |
Quality Earnings: 787 has high quality earnings.
Growing Profit Margin: 787's current net profit margins (19.4%) are higher than last year (6.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 787's earnings have grown significantly by 38.3% per year over the past 5 years.
Accelerating Growth: 787's earnings growth over the past year (167.2%) exceeds its 5-year average (38.3% per year).
Earnings vs Industry: 787 earnings growth over the past year (167.2%) exceeded the Life Sciences industry -9.9%.
Return on Equity
High ROE: 787's Return on Equity (20%) is considered low.